Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EP-104GI

Other · developed by Eupraxia Pharmaceuticals

Phase 1/2 Most advanced trial
EPRX Developer
1 Registered trials

What is EP-104GI?

EP-104GI is an extended-release formulation of fluticasone propionate, a corticosteroid, supplied as a powder suspended in vehicle for administration into the gastrointestinal tract. It is studied in eosinophilic esophagitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Eupraxia Pharmaceuticals Inc. (EPRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05608681 Phase 1/2 Eosinophilic Esophagitis Recruiting EPRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eosinophilic Esophagitis

More from Eupraxia Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EPRX page.

Follow EPRX, the company behind EP-104GI

See EPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EPRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.